Cost impact of procalcitonin-guided decision making on duration of antibiotic therapy for suspected early-onset sepsis in neonates

Autor: A. J. L. M. Geraerds, Wendy van Herk, Martin Stocker, Salhab el Helou, Sourabh Dutta, Matteo S. Fontana, Frank A. B. A. Schuerman, Rita K. van den Tooren-de Groot, Jantien Wieringa, Jan Janota, Laura H. van der Meer-Kappelle, Rob Moonen, Sintha D. Sie, Esther de Vries, Albertine E. Donker, Urs Zimmerman, Luregn J. Schlapbach, Amerik C. de Mol, Angelique Hoffman-Haringsma, Madan Roy, Maren Tomaske, René F. Kornelisse, Juliette van Gijsel, Eline G. Visser, Annemarie M. C. van Rossum, Suzanne Polinder

Publikováno v: Critical Care, Vol 25, Iss 1, Pp 1-11 (2021)

Abstract Backgrounds The large, international, randomized controlled NeoPInS trial showed that procalcitonin (PCT)-guided decision making was superior to standard care in reducing the duration of antibiotic therapy and hospitalization in neonates sus

Externí odkaz: https://doaj.org/article/81f8bed465e94931874422ffb63889fc

Cost impact of procalcitonin-guided decision making on duration of antibiotic therapy for suspected early-onset sepsis in neonates

Autor: Albertine E Donker, Suzanne Polinder, Urs Zimmerman, Matteo Fontana, Martin Stocker, Sintha D. Sie, Juliette van Gijsel, Rob Moonen, René F. Kornelisse, Salhab el Helou, Madan Roy, Rita K van den Tooren-de Groot, Luregn J. Schlapbach, Esther de Vries, Jan Janota, Sourabh Dutta, Wendy van Herk, Angelique Hoffman-Haringsma, Jantien W Wieringa, Maren Tomaske, Eline G. Visser, Laura H van der Meer-Kappelle, A. J. L. M. Geraerds, Amerik C. de Mol, Frank A B A Schuerman, Annemarie M. C. van Rossum

Publikováno v: Critical Care, 25(1):367. BioMed Central Ltd.
Critical Care, 25:367. BioMed Central Ltd.
Critical Care, Vol 25, Iss 1, Pp 1-11 (2021)
Critical Care. Springer Science + Business Media
Geraerds, A J L M, van Herk, W, Stocker, M, el Helou, S, Dutta, S, Fontana, M S, Schuerman, F A B A, van den Tooren-de Groot, R K, Wieringa, JW, Janota, J, van der Meer-Kappelle, L H, Moonen, R, Sie, SD, de Vries, E, Donker, A E, Zimmerman, U, Schlapbach, L J, de Mol, AC, Hoffman-Haringsma, A, Masius, R, Tomaske, M, Kornelisse, R F, van Gijsel, J, Visser, E G, van Rossum, A M C & Polinder, S 2021, ' Cost impact of procalcitonin-guided decision making on duration of antibiotic therapy for suspected early-onset sepsis in neonates Open Access ', Critical Care . https://doi.org/10.1186/s13054-021-03789-x
Critical Care

Backgrounds The large, international, randomized controlled NeoPInS trial showed that procalcitonin (PCT)-guided decision making was superior to standard care in reducing the duration of antibiotic therapy and hospitalization in neonates suspected of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5b14d389a4440869bd643c4fe859553
https://doi.org/10.1186/s13054-021-03789-x

C-Reactive Protein, Procalcitonin, and White Blood Count to Rule Out Neonatal Early-onset Sepsis Within 36 Hours: A Secondary Analysis of the Neonatal Procalcitonin Intervention Study

Autor: Rita K van den Tooren-de Groot, Paul T. Heath, Juliette van Gijsel, Eline G. Visser, Dirk Lehnick, Salhab el Helou, Esther de Vries, Wendy van Herk, Frank A B A Schuerman, René F. Kornelisse, Maren Tomaske, Annemarie M. C. van Rossum, Madan Roy, Jantien W Wieringa, Frans B. Plötz, Jan Janota, Luregn J. Schlapbach, Sintha D. Sie, Urs Zimmerman, Laura H van der Meer-Kappelle, Niek B. Achten, Albertine E Donker, Angelique Hoffman-Haringsma, Martin Stocker, Rob Moonen, Sourabh Dutta, Amerik C. de Mol

Publikováno v: Clinical infectious diseases, 73(2), e383-e390. Oxford University Press
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73(2), e383-e390. Oxford University Press
Stocker, M, van Herk, W, el Helou, S, Dutta, S, Schuerman, F A B A, van den Tooren-de Groot, R K, Wieringa, JW, Janota, J, van der Meer-Kappelle, L H, Moonen, R, Sie, SD, de Vries, E, Donker, A E, Zimmerman, U, Schlapbach, L J, de Mol, AC, Hoffman-Haringsma, A, Roy, M, Tomaske, M, Kornelisse, R F, van Gijsel, J, Visser, E G, Plötz, F B, Achten, N B & van Rossum, A M C 2021, ' C-Reactive Protein, Procalcitonin, and White Blood Count to Rule Out Neonatal Early-onset Sepsis Within 36 Hours: A Secondary Analysis of the Neonatal Procalcitonin Intervention Study ', Clinical Infectious Diseases . https://doi.org/10.1093/cid/ciaa876
Clinical Infectious Diseases. Oxford University Press

BACKGROUND Neonatal early-onset sepsis (EOS) is one of the main causes of global neonatal mortality and morbidity, and initiation of early antibiotic treatment is key. However, antibiotics may be harmful. METHODS We performed a secondary analysis of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5106586d5c207cc098ccb6c84e287bc
https://pure.amc.nl/en/publications/creactive-protein-procalcitonin-and-white-blood-count-to-rule-out-neonatal-earlyonset-sepsis-within-36-hours-a-secondary-analysis-of-the-neonatal-procalcitonin-intervention-study(3fa753a2-f6e0-4588-8d23-e40078a15b98).html

Additional file 2 of Cost impact of procalcitonin-guided decision making on duration of antibiotic therapy for suspected early-onset sepsis in neonates

Autor: Geraerds, A. J. L. M., van Herk, Wendy, Stocker, Martin, el Helou, Salhab, Dutta, Sourabh, Fontana, Matteo S., Schuerman, Frank A. B. A., van den Tooren-de Groot, Rita K., Wieringa, Jantien, Janota, Jan, van der Meer-Kappelle, Laura H., Moonen, Rob, Sie, Sintha D., de Vries, Esther, Donker, Albertine E., Zimmerman, Urs, Schlapbach, Luregn J., de Mol, Amerik C., Hoffman-Haringsma, Angelique, Roy, Madan, Tomaske, Maren, Kornelisse, René F., van Gijsel, Juliette, Visser, Eline G., van Rossum, Annemarie M. C., Polinder, Suzanne

Overview cost prices in 2015€.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2052830c9760e90532dbade5d325dc13

Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis:a multicentre, randomised controlled trial (NeoPIns)

Autor: B Manai, M Stocker, Fam van den Dungen, Mathias Nelle, Matteo Fontana, Faba Schuerman, L de Ligt, M Visnovska, S Alliston, SD Sie, Mark Alan Fontana, Angelique Hoffman-Haringsma, S Hill, MM van Weissenbruch, René F. Kornelisse, Albertine E Donker, D Glauser, Wendy van Herk, R Kornelisse, N Lanz, Laura H van der Meer-Kappelle, Groot A van Rossum, Sintha D. Sie, R Moonen, S Dutta, EG Visser, M Strik, W van Herk, Rob Moonen, LJ Schlapbach, Salhab el Helou, Urs Zimmerman, Martin Stocker, A Donker, M Batstra, Jantien W Wieringa, Luregn J. Schlapbach, Peter Andriessen, GJ van der Geijn, Wim C. J. Hop, J van der Velden, AC de Mol, U Zimmerman, LH van der Meer-Kappelle, A van Rossum, David Pogorzelski, Sten P. Willemsen, S Siiskonen, Jan Janota, A Haringsma, Ipe Gondriet, Juliette van Gijsel, S el Helou, Y.B. de Rijke, S Willemsen, Sourabh Dutta, Esther de Vries, S Hoekstein, E.G.E. de Vries, Mac Broeren, M Hofhuis, Amerik C. de Mol, J van Gijsel, Eline G. Visser, J Bolt-Wieringa, V Grey, Frank A B A Schuerman, K Hauff, Maren Tomaske, Marc-André Roy, S Donker, A Bakry, Madan Roy, HK van den Tooren-de, S Kittanakom, J Janota, Daniel Stok, J Asch van Wijk, K Kalaniti, M Tomaske, Annemarie M. C. van Rossum, Rita K van den Tooren-de Groot

Publikováno v: Stocker, M, van Herk, W, el Helou, S, Dutta, S, Fontana, M S, Schuerman, F A B A, van den Tooren-de Groot, R K, Wieringa, J W, Janota, J, van der Meer-Kappelle, L H, Moonen, R, Sie, S D, de Vries, E, Donker, A E, Zimmerman, U, Schlapbach, L J, de Mol, A C, Hoffman-Haringsma, A, Roy, M, Tomaske, M, Kornelisse, R F, van Gijsel, J, Visser, E G, Willemsen, S P, van Rossum, A M C & NeoPInS Study Group 2017, ' Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis : a multicentre, randomised controlled trial (NeoPIns) ', The Lancet, vol. 390, no. 10097, pp. 871-881 . https://doi.org/10.1016/S0140-6736(17)31444-7
Lancet (UK), 390(10097), 871-881. Elsevier Ltd.
The Lancet, 390(10097), 871-881. Elsevier Limited

Background Up to 7% of term and late-preterm neonates in high-income countries receive antibiotics during the first 3 days of life because of suspected early-onset sepsis. The prevalence of culture-proven early-onset sepsis is 0·1% or less in high-i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2fcd49b436336d996370910b9ffacc0
https://research.vumc.nl/en/publications/c69a05d1-c20f-4c78-ae0e-2da2022b86ae